2026 Interim Report
Filed with HKEX · Stock code 2652 · · 59 pages · English
2 DEFINITIONS 6 CORPORATE INFORMATION 8 FINANCIAL HIGHLIGHTS 9 MANAGEMENT DISCUSSION AND ANALYSIS 24 CORPORATE GOVERNANCE AND OTHER INFORMATION 37 INDEPENDENT REVIEW REPORT 38 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS 39 INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 40 INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 41 INTERIM CONDENSED CONSOLID
Earlier from CF PharmTech
- Next day disclosure return
- Voluntary announcement ICF004 completes enrolment and dosing of first healthy volunteer in phase i clinical trial
- List of Directors and their Roles and Functions
- Change in board lot size
Later from CF PharmTech
- Voluntary announcement voluntary extension of lock-up period for shares held by core management by six months
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow CF PharmTech into a list and get an email when it puts out news.
Follow CF PharmTech